Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.60 |
| ▸ | FABP4 | P15090 | 5/20 | 0.57 |
| ▸ | FABP3 | P05413 | 4/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8512694 | 0.98 | PBRM1 (0.58) | PBRM1FABP4FABP3PLK1ALDH1A1 | |
| SCHEMBL9840008 | 0.85 | ALDH1A1 (0.47) | PBRM1FABP4FABP3ALDH1A1MEN1 | |
| SCHEMBL7748934 | 0.83 | ALDH1A1 (0.46) | PBRM1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL31488086 | 0.81 | PBRM1 (0.57) | PBRM1FABP4FABP3PLK1ALDH1A1 | |
| SCHEMBL9609179 | 0.81 | POLB (0.53) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL6801278 | 0.81 | PBRM1 (0.57) | PBRM1FABP4FABP3PLK1ALDH1A1 | |
| SCHEMBL2137697 | 0.81 | PBRM1 (0.60) | PBRM1FABP4FABP3PLK1ALDH1A1 | |
| SCHEMBL22237905 | 0.81 | PBRM1 (0.60) | PBRM1FABP4FABP3PLK1ALDH1A1 | |
| SCHEMBL3816160 | 0.80 | ALDH1A1 (0.42) | PBRM1FABP4FABP3ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL28022291 | 0.79 | PBRM1 (0.58) | PBRM1FABP4FABP3PLK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682120-B1 | Stable laquinimod preparations | TEVA PHARMA (IL) | 2016-08-03 | — | — | EP | disclosed |
| US-9340307-B2 | Stable laquinimod preparations | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-05-17 | — | — | US | disclosed |
| EP-2977049-A1 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-01-27 | — | — | EP | disclosed |
| US-9102592-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | MAPI PHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-9102592-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | MAPI PHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-9102592-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | MAPI PHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2015-02-19 | — | — | US | disclosed |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2015-02-19 | — | — | US | disclosed |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2015-02-19 | — | — | US | disclosed |
| US-8865742-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium | MAPI PHARMA LTD. (IL) | 2014-10-21 | — | — | US | disclosed |
| CN-101087779-A | Selected benzofuran derivatives | ARPIDA AG (CH) | 2007-12-12 | — | — | CN | disclosed |
| EP-1838704-A1 | SELECTED BENZOFURAN DERIVATIVES | Arpida AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072370-A1 | SELECTED BENZOFURAN DERIVATIVES | ARPIDA AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-6844435-B2 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030207902-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1309596-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6489328-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002014319-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | PBRM1 2285/4885FABP4 4518/4885FABP3 3427/4885 |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | TLR7, NQO1, NQO2 | PBRM1 612/4885FABP4 4025/4885FABP3 4695/4885 |
| US-20030207902-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | PBRM1 2285/4885FABP4 4518/4885FABP3 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.